ACKNOWLEDGEMENTS
This study did not receive funding from any external entity, be it a personality or institution. All the authors are affiliated with the Department of Medicine of the Philippine General Hospital. We would like to acknowledge the insights and inputs by our consultant colleagues from the Division of Nephrology of our department. We would also like to thank the Clinical Research Division of our department for the technical assistance provided.
REFERENCES
  1. National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American Journal of Kidney Disease . 2002; 39(1):1-266.
  2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International Supplements . 2013; 3(1):1-150.
  3. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.New England Journal of Medicine . 2004; 351:1296-1305.
  4. Levey AS, Coresh J. Chronic kidney disease. Lancet . 2012; 379:165–180.
  5. Romagnani P, Remuzzi G, Glassock R, Levin A, Jager KJ, Tonelli M, et al. Chronic kidney disease. Nature Reviews Disease Primers . 2017; 3:17088.
  6. Philippine Health Insurance Corporation. 2017 Stats and Charts [internet]. PhilHealth . 2017. Available from https://www.philhealth.gov.ph/about_us/statsncharts/snc2017.pdf.
  7. Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, et al. European Uremic Toxin Work Group (EUTox): Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clinical Journal of the American Society of Nephrology . 2009; 4:1551–1558.
  8. Liabeuf S, Barreto DV, Barreto FC, Meert N, Glorieux G, Schepers E, et al. European Uremic Toxin Work Group (EUTox): Free p-cresyl sulfate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrology Dialysis Transplantation . 2010; 25:1183–1191.
  9. Meijers BK, Claes K, Bammens B, de Loor H, Viaene L, Verbeke K, et al. p-Cresol and cardiovascular risk in mild-to-moderate kidney disease.Clinical Journal of the American Society of Nephrology . 2010; 5:1182–1189.
  10. Wu IW, Hsu KH, Lee CC, Sun CY, Hsu HJ, Tsai CJ, et al. p-Cresyl sulfate and indoxyl sulphate predict progression of chronic kidney disease. Nephrology Dialysis Transplantation . 2011; 26:938–947.
  11. Niwa T, Yazawa T, Ise M, Sugano M, Kodama T, Uehara Y, Maeda K. Inhibitory effect of oral sorbent on accumulation of albumin-bound indoxyl sulfate in serum of experimental uremic rats. Nephron . 1991; 57:84-88.
  12. Akiyama Y, Takeuchi Y, Kikuchi K, Mishima E, Yasuaki Y, Suzuki C, et al. A metabolomic approach to clarifying the effect of AST-120 on 5/6 nephrectomized rats by capillary electrophoresis with mass spectrometry (CE-MS). Toxins . 2012; 4(11):1309–22.
  13. Okada K, Matsumoto K, Takahashi S. Uremic toxins adsorbed by AST-120 promote tubular hypertrophy and interstitial fibrosis in nephrectomized rats. Kidney & Blood Pressure Research . 2005; 28(1):8–13.
  14. Bolati D, Shimizu H, Niwa T. AST-120 ameliorates epithelial-to-mesenchymal transition and interstitial fibrosis in the kidneys of chronic kidney disease rats. Journal of Renal Nutrition . 2012; 22(1):176–80.
  15. Konishi K, Nakano S, Tsuda S, Nakagawa A, Kigoshi T, Koya D. AST-120 (Kremezin) initiated in early stage chronic kidney disease stunts the progression of renal dysfunction in type 2 diabetic subjects.Diabetes Research and Clinical Practice . 2008; 81:310–315.
  16. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Suzuki T, Ueda Y, Yamagishi S. Oral adsorbent AST-120 ameliorates tubular injury in chronic renal failure patients by reducing proteinuria and oxidative stress generation. Metabolism . 2011; 60:260–264.
  17. Hatakeyama S, Yamamoto H, Okamoto A, Imanishi K, Tokui N, Okamoto T, et al. Effect of an oral adsorbent, AST-120, on dialysis initiation and survival in patients with chronic kidney disease. International Journal of Nephrology. 2012; 376128.